ingredient one or more of the Regulated Chemicals. "Products" shall also include any future

. 20

28 ///

Products that are manufactured by or on behalf of Defendant for sale to consumers in California under any product name or brand, whether a current or new name and/or brand.

1.3 Plaintiff and Defendant will be referred to collectively as the "Parties" or individually as a "Party."

#### 2. Background.

- 2.1 Ms. Buckland is the Executive Director of the California Women's Law Center ("CWLC"), a non-profit California corporation. Since its founding in 1989, CWLC has served as a unique advocate in California, working in collaboration with others to protect, secure and advance the comprehensive civil rights of women and girls. The CWLC works to ensure, through systemic change, that life opportunities for women and girls are free from unjust social, economic, and political constraints. CWLC is based in Los Angeles, and was incorporated under the laws of the State of California in 1989.
- 2.2 Ms. Buckland is a "consumer" within the meaning of the California Consumer Legal Remedies Act ("CLRA"), California Civil Code ("Civil Code") § 1761(d). Ms. Buckland is also a "person" within the meaning of California Business and Professions ("B&P") Code §§ 17201, 17204 and 17506. She brought and settles this lawsuit on her own behalf and, to the fullest extent permitted by law, on behalf of the general public. CWLC is a "person" within the meaning of Health & Safety Code §§ 25249.7(d) and 25249.11(a). CWLC brings its Proposition 65 cause of action in the public interest.
- 2.3 Defendant is a New York corporation d/b/a as Country Life, LLC, with its principal place of business and/or headquarters located at 180 Motor Parkway, Hauppauge, New York 11788. Defendant indirectly sold through unrelated customers outside of California, who then resold to California consumers Products, all of which Plaintiffs allege contain a chemical or chemicals listed by the State of California as known to cause cancer and/or reproductive toxicity pursuant to the Safe Drinking Water and Toxic Enforcement Act of 1986, California Health and Safety Code § 25249.5 et seq. ("Proposition 65"); Title 22, California Code of Regulations § 12000 et seq.

- 2.4 Beginning on or about February 9, 2006, CWLC served Defendant and each of the appropriate public enforcement agencies with a "60-Day Notice" that provided Defendant and the public enforcement agencies with a notice alleging that Defendant was in violation of Proposition 65 for failing to warn the purchasers of, and individuals using, the Products that the use of the Products exposes them to Regulated Chemicals. Defendant stipulates for the purpose of this Consent Judgment that the 60-Day Notice sent to it is adequate to comply with Title 22, California Code of Regulations § 12903. None of the public enforcement agencies has commenced and begun diligently prosecuting an action against Defendant for such alleged violations.
- 2.5 On or about February 9, 2006, Ms. Buckland, pursuant to Civil Code § 1782 served Defendant with a notice letter (the "CLRA Notice" -- collectively with the 60-Day Notice, "Notices") via certified mail, return receipt requested, stating *inter alia* as follows:

These Products have been sold to literally millions of California consumers without any of the noticed companies providing a clear and reasonable warning prior to their purchase by a consumer that the Progesterone, Medroxyprogesterone acetate, Testosterone and its esters, Methyltestosterone, Testosterone cypionate, and/or Testosterone enanthate in these Products are chemicals known to be carcinogens and/or reproductive toxins by the State of California. Nor has any of the noticed companies disclosed the potential adverse health effect risks posed by exposure to these chemicals in these Products because Progesterone, Medroxyprogesterone acetate, Testosterone and its esters, Methyltestosterone, Testosterone cypionate, and/or Testosterone enanthate in these Products are chemicals regulated as drugs by the U.S. Food and Drug Administration under the federal Food, Drug and Cosmetic Act. These omissions of material facts constitute deceptive representations and misrepresentations, failure to disclose that the product is a regulated drug, and misbranding in violation of § 1770 of the CLRA.

2.6 On December 7, 2005, Ms. Buckland and CWLC filed their initial complaint entitled *Buckland, et al. v. Threshold Enterprises, Ltd., et al.*, No. BC344046, in the Los Angeles County Superior Court. On January 24, 2006, Plaintiffs filed their First Amended Complaint, which is the now-operative complaint in this matter (the "First Amended Complaint"). On April 21, 2006, Defendant was added to the First Amended Complaint as a DOE Defendant pursuant to Code of Civil Procedure § 474. CWLC alleged violations of Proposition 65 against

4 3. <u>Injunctive Relief.</u>

3.1 <u>Defendant Has Exited the Market.</u>

Defendant has previously voluntarily exited the California market for the Products. If Defendant chooses to re-enter the California market for these Products, Defendant shall comply with the terms set forth in the following paragraphs 3.2 and 3.3.

Defendant, while Ms. Buckland alleged violations of the CLRA, Business & Professions Code §§ 17200 et seq. and 17500 et seq., and Civil Code §§ 1709 and 1710, against Defendant, respectively.

- 2.7 For purposes of this Consent Judgment only, the Parties stipulate that this Court has jurisdiction over the allegations of the violations contained in the Notices and the First Amended Complaint, and personal jurisdiction over Defendant as to the acts or omissions alleged in the First Amended Complaint; that venue is proper in the County of Los Angeles; and that this Court has jurisdiction to enter this Consent Judgment.
- 2.8 Defendant denies that the Products have been or are in violation of any law, and further contends that all Products have been and are safe for use as directed. However, the Parties desire to resolve this matter (including the Notices, First Amended Complaint and all related matters) without further litigation or cost.
- 2.9 The Parties enter into this Consent Judgment to settle certain disputed claims as alleged in the Notices and the First Amended Complaint, to avoid prolonged and costly litigation, and to promote the public interest. By executing and complying with this Consent Judgment, no Party admits any facts or conclusions of law including, but not limited to, any facts or conclusions of law regarding any violations of the California Legal Remedies Act (Civil Code § 1750 et seq.), the Unlawful Competition Law (B&P Code § 17200 et seq.), the False Advertising Law (B&P Code § 17500 et seq.), Civil Code §§1709 and 1710, Proposition 65 (Health & Safety Code § 25249.5 et seq.) or any other statutory, common law or equitable claim or requirement relating to or arising from Defendant's Products. This Consent Judgment shall not be construed as an admission by Defendant as to any of the allegations in the 60-Day Notice, the CLRA Notice or the First Amended Complaint.

# 3.2 Future Product Sales Require a Warning.

Pursuant to Civil Code § 1782(d), and B&P Code §§ 17203 and 17535, the sale of a Product by Defendant shall be accompanied by a warning. This warning shall be provided both by (a) product labeling pursuant to Paragraph 3.2.1; and (b) warnings for any mail order and Internet sales pursuant to Paragraph 3.2.2.

### 3.2.1 **Product Label Warnings.**

At the earliest such time when, in the ordinary course of business, new labels for the Products are printed on or after January 1, 2007, Defendant shall include (in the same type size as the surrounding, non-heading text) the following warning on the label of each of its Products that it manufactures and ships for sale directly or indirectly to consumers in California, including the specific name or names of the Regulated Chemicals present in the Product:

"WARNING: This product contains [Progesterone,
Medroxyprogesterone acetate, Testosterone and its esters,
Methyltestosterone, Testosterone cypionate, and/or Testosterone
enanthate], a chemical(s) known to the State of California to cause
cancer. Consult with your physician before using this product."

## 3.2.2 Additional Warnings for Mail Order or Internet Sales.

If Defendant directly sells a Product by mail order or over the Internet to consumers in the state of California on or after the date that is 90 days after the entry of this Consent Judgment by the court, the following additional requirements shall apply:

- (1) For such mail order sales, the warning language required under this Consent Judgment at paragraph 3.2.1 shall be included in the mail order catalogue, either on the same page as any order form, or on the same page(s) upon which the Product's price is listed, in the same type size as the surrounding, non-heading text.
- (2) For such Internet sales, the warning language required under this Consent Judgment at paragraph 3.2.1 shall be displayed (in the same type size as the surrounding, non-heading text) in one or more of the following ways: (a) on the same page upon which the Product is displayed or referenced; (b) on the same page as any order form for any Product;

(c) on the same page as the price for the Product is displayed; (d) on one or more pages displayed to a purchaser over the Internet or via electronic mail during the checkout and order confirmation process for sale of a Product; or (e) in any manner such that it is likely to be read and understood by an ordinary individual under customary business conditions prior to the purchase of the Product.

#### 3.3 Compliance with Federal Law.

Pursuant to Civil Code § 1782(d) and B&P Code §§ 17203 and 17535, and effective when, in the ordinary course of business, new labels and advertising, marketing, mail order catalog or Internet-based descriptions of each of its respective Products are printed or posted electronically on or after January 1, 2006, Defendant agrees to remove any "health-related" claims (as that term is used by the U.S. Food and Drug Administration under Title 21 United States Code § 321(g) and Title 21 Code of Federal Regulation, Part 310.530, Over-The-Counter Topically Applied Hormone Drug Products) made by Defendant for any of its respective Products.

## 4. <u>Financial Settlement and Attorneys' Fee Payments.</u>

- 4.1 In lieu of damages or penalties, Defendant shall pay to the CWLC the sum of \$1,500.00 ("settlement amount"), and shall make that payment to the Client Trust Account of the Carrick Law Group P.C., by wire transfer, certified or bank check in immediately available funds. This settlement amount shall be due and payable within five (5) calendar days after the date of notice of entry of this Consent Judgment. This settlement amount shall be disbursed promptly thereafter by the Carrick Law Group P.C. to the CWLC.
- 4.2 <u>Attorneys Fees and Costs.</u> The Parties shall each bear their own attorneys' fees and costs.

### 5. <u>Claims Covered and Released.</u>

This Consent Judgment includes the resolution of all actual and potential claims that were considered or could have been brought by Plaintiffs regarding the Regulated Chemical(s) in Defendant's Products. This Consent Judgment is a final and binding resolution between Plaintiff and Defendant of any and all alleged violations of Proposition 65, the CLRA, the Unfair

Competition Law, the False Advertising Law, Civil Code §§ 1709 and 1710, or any other law that was or could have been asserted by Plaintiff arising from or related to Defendant's Products up through the date of entry of this Consent Judgment, including, but not limited to any claims for attorneys' fees and costs (collectively "Claims"). Plaintiffs hereby release the Defendant Releasees (as defined below) and waive all rights to institute or participate in, directly or indirectly, any form of legal action seeking any form of relief (whether injunctive, compensatory, punitive, or otherwise) arising from the Claims against Defendant, its officers, directors, employees, agents, attorneys, consultants, representatives, shareholders, parents, subsidiaries, affiliates, divisions, predecessors, successors, subdivisions, downstream distributors, downstream retailers, downstream customers, and upstream suppliers of the raw materials used in the Products (the "Defendant Releasees"); however, Plaintiffs cannot and expressly do not release any other claims, including specifically and without limitation any personal injury or directly related claims, that could be brought by any other individual or organization. Defendant hereby releases each Plaintiff from and against any claims arising out of each Plaintiff's notices and their filing or prosecution of this action. Each Party respectively waives any right to appeal or other review of this Consent Judgment, except as expressly provided in this Consent Judgment.

- 6. Covenant Not To Sue. The Parties covenant and agree that with regard to those matters that the Parties have herein released and that are described above, neither Plaintiffs nor Defendant will ever institute a lawsuit or administrative proceedings against the other, nor shall Plaintiffs or Defendant assert any claim of any nature against any person or entity hereby released with regard to any such matters which have been released. However, nothing in this paragraph shall be interpreted to preclude enforcement of this Consent Judgment pursuant to paragraph 7 below.
- 7. <u>Enforcement of Consent Judgment</u>. Any Party may, by noticed motion or order to show cause before the Superior Court of Los Angeles, enforce this Consent Judgment. To enforce this Consent Judgment, any Party must first give written notice of any violation of this Consent Judgment alleged to have occurred to the Party alleged to be in violation. The Parties

shall meet and confer in good faith and attempt to resolve the alleged violation. If a resolution is not reached within thirty (30) days of the date of the notice, the aggrieved Party may move the Court to hear and resolve the dispute. The prevailing Party in any proceeding brought to enforce this Consent Judgment shall be entitled to recover from the other Party the prevailing Party's reasonable attorneys' fees and costs incurred in the investigation and prosecution of such an enforcement proceeding.

- 8. Application of Consent Judgment. Paragraphs 3, 5 and 6 of this Consent Judgment shall apply to, be binding upon and inure to the benefit of the Parties, Ms. Buckland and the CWLC, their divisions, subdivisions, subsidiaries, affiliates, successors, predecessors and assigns, and the directors, officers, employees, legal counsel, and agents of each of them, as applicable, and will inure to the benefit of the Parties' parent companies, all suppliers, distributors, wholesalers, retailers and contract manufacturers, and all of their respective directors, officers, employees, legal counsel, and agents. This Consent Judgment shall have no effect on products sold by Defendant and shipped to customers for use outside the State of California; provided that the products are not sold directly or indirectly to consumers in California.
- 9. <u>Modification/Termination of Consent Judgment</u>. This Consent Judgment may be modified or terminated upon written agreement of Defendant and Plaintiffs, with approval of the Court, or upon noticed motion for good cause shown. However, the Parties shall meet and confer in good faith and attempt to mutually agree upon any modification prior to the filing of any motion. The Parties acknowledge that new toxicological information or exposure assessments concerning hazardous substances and testing methodologies are continuously becoming available, and that statutory and regulatory standards applicable to the Products may evolve in the future, either of which may establish good cause for modification of this Consent Judgment. The burden of proof in any such motion shall be on the moving party to establish such good cause. The prevailing Party in any such motion shall be entitled to recover from the other Party the prevailing Party's reasonable attorneys' fees and costs incurred in the preparation and prosecution of such a motion.

5

10 11

12 13

15

16

18

19

17

20 21

22

23 24

25 26

27 28

- 10. Governing Law. This Consent Judgment shall be governed by, and construed in accordance with, the laws of the State of California.
- Entire Agreement. The Parties declare and represent that no promise, inducement or 11. other agreement has been made conferring any benefit upon any party except those contained herein and that this Consent Judgment contains the entire agreement pertaining to the subject matter hereof. This Consent Judgment supersedes any prior or contemporaneous negotiations, representations, agreements and understandings of the Parties with respect to such matters, whether written or oral. Parol evidence shall be inadmissible to show agreement by, between or among the Parties to any term or condition contrary to or in addition to the terms and conditions contained in this Consent Judgment. The Parties acknowledge that each has not relied on any promise, representation or warranty, expressed or implied, not contained in this Consent Judgment except with regard to that certain declaration executed under penalty of perjury by the Defendant providing information that induced Ms. Buckland and CWLC to enter into the financial terms of this Consent Judgment, which declaration may be used solely as evidence in any future enforcement proceeding brought pursuant to Paragraph 7 above.
- 12. **Challenges.** Subject to their rights to apply for a modification of this Consent Judgment for good cause shown under Paragraph 9 hereof, the Parties agree that they, individually or collectively, will not seek to challenge or to have determined invalid, void or unenforceable any provision of this Consent Judgment or this Consent Judgment itself. The Parties understand that this Consent Judgment contains the relinquishment of legal rights and each Party has, as each has deemed appropriate, sought the advice of legal counsel, which each of the Parties has encouraged the other to seek. Further, no Party has reposed trust or confidence in any other Party so as to create a fiduciary, agency or confidential relationship.
- 13. **Construction.** This Consent Judgment has been jointly negotiated and drafted. The language of this Consent Judgment shall be construed as a whole according to its fair meaning and not strictly for or against any Party.
- Authority to Stipulate to Consent Judgment. Each signatory to this Consent Judgment 14. represents and warrants that each signatory has all requisite power, authority and legal right

1	17.3 All correspondence and notices required by this Consent Judgment to Defendant				
2	shall be sent to Defendant as follows:				
3 4 5 6 7	Michael E. Cirenza Consac Industries, Inc., d/b/a Country Life, LLC 180 Motor Parkway Hauppauge, New York 11788 Tel: (631) 232-5482 Fax: (631) 434-4791 E-mail: michaelc@country-life.com  Mith a copy to: Thomas J. Killeen, Esq. Partner Farrell Fritz PC 1320 Reckson Plaza Uniondale, New York 11556 Tel: (516) 227-0631 Fax: (516) 336-2203 E-mail: tkilleen@farrellfritz.com				
8	18. Entry of Stipulation For Entry of Consent Judgment Required. This Consent				
9	Judgment shall be null and void, and without any force or effect, unless fully approved as				
10	required by law and entered by the Court. If the Court does not enter this Consent Judgment, the				
11	execution thereof by Defendant or Plaintiffs shall not be construed as an admission by Defendant				
12	or Plaintiffs of any fact, issue of law or violation of law.				
13	19. <u>Jurisdiction</u> . This Court shall retain jurisdiction of this matter to implement this Consent				
14	Judgment.				
15	20. <u>Compliance with Reporting Requirements</u> . Plaintiffs shall comply with the reporting				
16	form requirements referred to in Health and Safety Code section 25249.7(f) and established in				
17	Title 11 of the California Code of Regulations sections 3000-3008. Copies of all such reports				
18	shall be supplied as provided in Paragraph 18.2.				
19					
20					
21					
22					
23					
24					
25					
26					
27					
28	1//				

1	21.	Non-Interference in Settlement A	pproval Process. The Parties will cooperate, as well		
2	as use their respective best efforts, to secure the Attorney General's approval of this Consent				
3	Judgment, and not to seek his disapproval of any portion of this Consent Judgment.				
4	IT IS SO STIPULATED.				
5		-c. latool			
6	Date:	September 24, 2006	KATHERINE LEE BUCKLAND, an individual		
7		·	VA RUN		
8			By: Latherine LEE BUCKLAND		
9					
10		CXXXX4			
11	Date:	September 2: 2006	CALIFORNIA WOMEN'S LAW CENTER		
12			Valorial pr Russ		
13			By: La Thaine (20 Buell  Executive Director		
14					
15					
16	Date:	September <u>25,</u> 2006	CONSAC INDUSTRIES, INC., a New York corporation d/b/a COUNTRY LIFE, LLC, a New		
17			York limited liability company		
18			M. 1157/		
19			By: Michael E. Cirenza		
20			Executive Vice President and Chief Financial Officer		
21					
22	1				
23					
24			·		
25					
26					
27					
28			12 [PROPOSED] FINDINGS & ORDER		
	Printe	d on Recycled Paper	12 [PROPOSED] FINDINGS & ORDER Consac Industries, Inc., d/b/a Country Life, LLC		

1	21.	Non-Interference in Settlement A	pproval Process. The Parties will cooperate, as well		
2	as use their respective best efforts, to secure the Attorney General's approval of this Consent				
3	Judgment, and not to seek his disapproval of any portion of this Consent Judgment.				
4	IT IS SO STIPULATED.				
5		•			
6	Date:	September, 2006	KATHERINE LEE BUCKLAND, an individual		
7					
8			By:KATHERINE LEE BUCKLAND		
9			KATHERINE LEE BUCKLAND		
10					
1	Date:	September, 2006	CALIFORNIA WOMEN'S LAW CENTER		
12		•			
۱3			By:Executive Director		
14	·		Executive Director		
15					
16	Date:	September <b>25</b> , 2006	CONSAC INDUSTRIES, INC., a New York corporation d/b/a COUNTRY LIFE, LLC, a New		
17			York limited liability company		
18			11/1/57/		
19			By: Michael E Circuit		
20			Executive Vice President		
21			and Chief Financial Officer		
22					
23					
24					
25					
26					
27					
28					
	<u></u>	· · · · · · · · · · · · · · · · · · ·	12 IDDODOSEDI FINIDINGS & OPDE		